Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular events.

The findings suggest weight loss drugs independently affect heart health risks, researchers said. View on euronews ...

A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.

The San Diego-based biotech has been evaluating the oral NLRP3 inhibitor, dubbed VTX3232, in a phase 2 study of 175 patients ...

Shares of Ventyx Biosciences (NASDAQ:VTYX) continued to climb with a nearly 100% rise in the premarket on Thursday after the ...

The drug’s effects on cardiovascular and inflammation markers outshined its failure to spur weight loss, analysts wrote.

Researchers say GLP-1 drugs prescribed for weight loss like Ozempic and Mounjaro are more effective at reducing heart health risks in people with type 2 diabetes than other types of glucose-lowering ...

An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in ...

A comparative effectiveness study of glucose-lowering drugs finds the GLP-1 receptor agonists most protective against ...

According to a new study, the weight loss drug semaglutide could have wider benefits regardless of how many kilograms people lose.The new research primarily suggests that shrinking waist size-a ...

Researchers found cardiovascular drugs were associated with 24.7 percent of all medication errors, followed by antibiotics at 19.1 percent, electrolytes at 11.3 percent, endocrine drugs at 8.8 percent ...

In combination, two commonly used heart drugs reverse fat accumulation in the liver, a study in animals has shown.